Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland)

D Hayes-Ryan, A S Khashan, K Hemming, C Easter, D Devane, D J Murphy, A Hunter, A Cotter, F M McAuliffe, J J Morrison, F M Breathnach, E Dempsey, L C Kenny, K O'Donoghue, PARROT Ireland trial group, S Kappala, N Murphy, E Tully, M Dowling, J O'Leary, R Keane, A Murphy, B McElroy, E Snapes, D Hayes-Ryan, A S Khashan, K Hemming, M Daly, E Ní Bhraonáin, D Devane, D Murphy, A Hunter, A Cotter, F M McAuliffe, J J Morrison, F M Breathnach, E Dempsey, L C Kenny, K O'Donoghue, N Barry, N Buckley, K Corry, C Dunney, J Courtney, P Gargan, L Heaphy, A Kearney, L Murphy, M Murphy, C Mulcahy, C Ni Laighin, C Nolan, A Warde, D Hayes-Ryan, A S Khashan, K Hemming, C Easter, D Devane, D J Murphy, A Hunter, A Cotter, F M McAuliffe, J J Morrison, F M Breathnach, E Dempsey, L C Kenny, K O'Donoghue, PARROT Ireland trial group, S Kappala, N Murphy, E Tully, M Dowling, J O'Leary, R Keane, A Murphy, B McElroy, E Snapes, D Hayes-Ryan, A S Khashan, K Hemming, M Daly, E Ní Bhraonáin, D Devane, D Murphy, A Hunter, A Cotter, F M McAuliffe, J J Morrison, F M Breathnach, E Dempsey, L C Kenny, K O'Donoghue, N Barry, N Buckley, K Corry, C Dunney, J Courtney, P Gargan, L Heaphy, A Kearney, L Murphy, M Murphy, C Mulcahy, C Ni Laighin, C Nolan, A Warde

Abstract

Objective: To determine whether the addition of placental growth factor (PlGF) measurement to current clinical assessment of women with suspected pre-eclampsia before 37 weeks' gestation would reduce maternal morbidity without increasing neonatal morbidity.

Design: Stepped wedge cluster randomised control trial from 29 June 2017 to 26 April 2019.

Setting: National multisite trial in seven maternity hospitals throughout the island of Ireland PARTICIPANTS: Women with a singleton pregnancy between 20+0 to 36+6 weeks' gestation, with signs or symptoms suggestive of evolving pre-eclampsia. Of the 5718 women screened, 2583 were eligible and 2313 elected to participate.

Intervention: Participants were assigned randomly to either usual care or to usual care plus the addition of point-of-care PlGF testing based on the randomisation status of their maternity hospital at the time point of enrolment.

Main outcomes measures: Co-primary outcomes of composite maternal morbidity and composite neonatal morbidity. Analysis was on an individual participant level using mixed-effects Poisson regression adjusted for time effects (with robust standard errors) by intention-to-treat.

Results: Of the 4000 anticipated recruitment target, 2313 eligible participants (57%) were enrolled, of whom 2219 (96%) were included in the primary analysis. Of these, 1202 (54%) participants were assigned to the usual care group, and 1017 (46%) were assigned the intervention of additional point-of-care PlGF testing. The results demonstrate that the integration of point-of-care PlGF testing resulted in no evidence of a difference in maternal morbidity-457/1202 (38%) of women in the control group versus 330/1017 (32%) of women in the intervention group (adjusted risk ratio (RR) 1.01 (95% CI 0.76 to 1.36), P=0.92)-or in neonatal morbidity-527/1202 (43%) of neonates in the control group versus 484/1017 (47%) in the intervention group (adjusted RR 1.03 (0.89 to 1.21), P=0.67).

Conclusions: This was a pragmatic evaluation of an interventional diagnostic test, conducted nationally across multiple sites. These results do not support the incorporation of PlGF testing into routine clinical investigations for women presenting with suspected preterm pre-eclampsia, but nor do they exclude its potential benefit.

Trial registration: ClinicalTrials.gov NCT02881073.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from HRB-MBCTNI for the submitted work; LK is a minority shareholder in an SME (https://metabolomicdiagnostics.com/) which has licensed IP pertaining to biomarkers predictive of pre-eclampsia that she has invented. The other authors declare no competing interests.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Fig 1
Fig 1
Consort flowchart of trial participants

References

    1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99. 10.1016/S0140-6736(05)17987-2
    1. Ireland NPEC. Severe maternal morbidity in Ireland . 2019. .
    1. Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and the Clinical Strategy and Programmes Division, Health Service Executive. The manangement of hypertension in pregnancy. 2016. .
    1. Brown MA, Magee LA, Kenny LC, et al. International Society for the Study of Hypertension in Pregnancy (ISSHP) . Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018;72:24-43. 10.1161/HYPERTENSIONAHA.117.10803
    1. Hayes Ryan D, McCarthy FP, O’Donoghue K, Kenny LC. Placental growth factor: A review of literature and future applications. Pregnancy Hypertens 2018;14:260-4. 10.1016/j.preghy.2018.03.003
    1. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991;88:9267-71. 10.1073/pnas.88.20.9267
    1. Levine RJ, Maynard SE, Qian C, et al. . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83. 10.1056/NEJMoa031884
    1. Álvarez-Fernández I, Prieto B, Rodríguez V, Ruano Y, Escudero AI, Álvarez FV. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis. Clin Chem Lab Med 2014;52:1159-68. 10.1515/cclm-2013-0901
    1. Chappell LC, Duckworth S, Seed PT, et al. . Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013;128:2121-31. 10.1161/CIRCULATIONAHA.113.003215
    1. Zeisler H, Llurba E, Chantraine F, et al. . Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016;374:13-22. 10.1056/NEJMoa1414838
    1. Barton JR, Woelkers DA, Newman RB, et al. PETRA (Preeclampsia Triage by Rapid Assay) Trial . Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study. Am J Obstet Gynecol 2020;222:259.e1-11. 10.1016/j.ajog.2019.09.003
    1. Sharp A, Chappell LC, Dekker G, et al. . Placental growth factor informed management of suspected pre-eclampsia or fetal growth restriction: The MAPPLE cohort study. Pregnancy Hypertens 2018;14:228-33. 10.1016/j.preghy.2018.03.013
    1. National Institute for Health and Clinical Excellence. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio) (Diagnostics guidance DG23). 2016. .
    1. Duhig KE, Myers J, Seed PT, et al. PARROT trial group . Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet 2019;393:1807-18. 10.1016/S0140-6736(18)33212-4
    1. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ 2015;350:h391. 10.1136/bmj.h391
    1. Hayes-Ryan D, Hemming K, Breathnach F, et al. . PARROT Ireland: placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial research study protocol. BMJ Open 2019;9:e023562. 10.1136/bmjopen-2018-023562
    1. Bland JM. Cluster randomised trials in the medical literature: two bibliometric surveys. BMC Med Res Methodol 2004;4:21-21. 10.1186/1471-2288-4-21
    1. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006;6:54-54. 10.1186/1471-2288-6-54
    1. Stolberg HO, Norman G, Trop I. Randomized controlled trials. AJR Am J Roentgenol 2004;183:1539-44. 10.2214/ajr.183.6.01831539
    1. National Institute for Health and Clinical Excellence. Hypertension in pregnancy: diagnosis and management (Clinical guideline CG107). 2010. .
    1. Hemming K, Taljaard M. Sample size calculations for stepped wedge and cluster randomised trials: a unified approach. J Clin Epidemiol 2016;69:137-46. 10.1016/j.jclinepi.2015.08.015
    1. Chappell LC, Duckworth S, Seed PT, et al. . Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013;128:2121-31. 10.1161/CIRCULATIONAHA.113.003215
    1. Martin J, Girling A, Nirantharakumar K, Ryan R, Marshall T, Hemming K. Intra-cluster and inter-period correlation coefficients for cross-sectional cluster randomised controlled trials for type-2 diabetes in UK primary care. Trials 2016;17:402. 10.1186/s13063-016-1532-9
    1. Hooper R, Bourke L. Cluster randomised trials with repeated cross sections: alternatives to parallel group designs. BMJ 2015;350:h2925. 10.1136/bmj.h2925
    1. Hemming K, Eldridge S, Forbes G, Weijer C, Taljaard M. How to design efficient cluster randomised trials. BMJ 2017;358:j3064. 10.1136/bmj.j3064
    1. Hemming K. The Shiny CRT Calculator: power and sample size for cluster randomised trials. .
    1. Campbell MK, Fayers PM, Grimshaw JM. Determinants of the intracluster correlation coefficient in cluster randomized trials: the case of implementation research. Clin Trials 2005;2:99-107. 10.1191/1740774505cn071oa
    1. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-6. 10.1093/aje/kwh090
    1. Hayes-Ryan D, Meaney S, Nolan C, O’Donoghue K. An exploration of women’s experience of taking part in a randomized controlled trial of a diagnostic test during pregnancy: A qualitative study. Health Expect 2020;23:75-83. 10.1111/hex.12969
    1. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials 2007;28:182-91. 10.1016/j.cct.2006.05.007
    1. Li F, Hughes JP, Hemming K, Taljaard M, Melnick ER, Heagerty PJ. Mixed-effects models for the design and analysis of stepped wedge cluster randomized trials: An overview. Stat Methods Med Res 2021;30:612-39. 10.1177/0962280220932962
    1. Thompson J, Davey C, Hayes R, Hargreaves J, Fielding K. swpermute: permutation tests for stepped-wedge cluster-randomised trials. Stata J 2019;19:803-19. 10.1177/1536867X19893624
    1. Roberge S, Sibai B, McCaw-Binns A, Bujold E. Low-dose aspirin in early gestation for prevention of preeclampsia and small-for-gestational-age neonates: meta-analysis of large randomized trials. Am J Perinatol 2016;33:781-5. 10.1055/s-0036-1572495
    1. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;(2):CD004659. 10.1002/14651858.CD004659.pub2
    1. Cerdeira AS, O’Sullivan J, Ohuma EO, et al. . Randomized interventional study on prediction of preeclampsia/eclampsia in women with suspected preeclampsia: INSPIRE. Hypertension 2019;74:983-90. 10.1161/HYPERTENSIONAHA.119.12739
    1. Griffin M, Seed PT, Webster L, et al. . Diagnostic accuracy of placental growth factor and ultrasound parameters to predict the small-for-gestational-age infant in women presenting with reduced symphysis-fundus height. Ultrasound Obstet Gynecol 2015;46:182-90. 10.1002/uog.14860

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner